Ferric Citrate in Managing Serum Phosphorus and Iron Deficiency in Anemic Chronic Kidney Disease (CKD) Subjects Not on Dialysis
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 149 participants.
Also called NCT01736397
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 149 participants
- Sponsor
- Registry
-
NCT01736397
-
- Other papers using this trial's data
- A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD Stages 3-5
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT01736397. Randomized; double masking; primary purpose treatment. Start 2012-11 (registry gives no type); primary completion 2013-11 (actual). Results posted on 2017-10-20.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Ferric Citrate in Managing Serum Phosphorus and Iron Deficiency in Anemic Chronic Kidney Disease (CKD) Subjects Not on Dialysis
- Condition
- Iron Deficiency
- Condition
- Iron Deficiency Anemia
- Intervention (Drug)
- Ferric Citrate
- Intervention (Drug)
- Placebo
- Lead sponsor
- Keryx Biopharmaceuticals
Record details
- Record id
cardio:ct-nct01736397- Content hash
7bb1ed8b1f845260d79caf4464acb00f7ec50d3602246cb69e42dc5939ff5a20